AEterna Zentaris, Inc.
Targeted anticancer agent advances into clinical development
Published in Healthcare Mergers, Acquisitions and Ventures Week, February 26th, 2005
AEterna Zentaris, Inc., (AEZ; AEZS) announced the initiation of a company-sponsored phase I dose-ranging study for its targeted anticancer agent AN-152, a novel cytotoxic conjugate that has the potential to selectively and specifically target certain types of cancer cells that express Luteinizing Hormone Releasing Hormones (LHRH) receptors (LHRH receptor positive tumors) and thereby may offer a better safety and efficacy profile as compared to the cytotoxic agent alone.
The phase I study, which will be conducted at university clinics in Gottingen and Frankfurt/Main in Germany, will evaluate the safety (including maximum tolerated dose and dose-limiting toxicity) and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
More Articles from Healthcare Mergers, Acquisitions and Ventures Week
- ATS Medical, Inc.
Medical device maker reports 28% increase in revenue - Accelerator Corporation
Cancer-focused Spaltudaq is third biotech company started by venture corporation - Accelrys, Inc.
Device firm reports decline in revenue - Adenosine Therapeutics, LLC
Drug discovery firm announces $3.5M in funding - Advanced Cell Technology
New CEO, chief scientific officer named at biotech firm - Advanced Magnetics, Inc.
Pharmaceutical firm reports loss of $0.32 per share - More from this issue of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
